Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.

A long way into the quest to vanquish cancer, our ears strain to hear the words, “Cancer is cured”—a yearning that can cloud our judgment.

The technology has wowed the field by all but obliterating some patients’ blood cancers, but solid malignancies present new challenges.

Following a spate of patient deaths in clinical trials testing modified T cells for the treatment of cancer, researchers work to reduce the treatment’s toxicity without sacrificing efficacy.

Tumors’ mutations can encode the seeds of their own destruction, in the form of immunogenic peptides recognized by T cells.

Neoantigens may serve as valuable targets for new immunotherapies.

The genomics pioneer shares the sessions she most looks forward to at this year’s American Association for Cancer Research annual meeting.

Billionaire Silicon Valley entrepreneur Sean Parker donates $250 million to unite the cancer research community around the common goal of developing new immunotherapies.

Understanding cancer’s relationship with the human microbiome could transform immune-modulating therapies.

Teenager Lauren Bendesky turned her cancer diagnosis on its head, using herself as a research subject to test potential therapies.

In recent years, research has demonstrated that microbes living in and on the mammalian body can affect cancer risk, as well as responses to cancer treatment.

Clinical cases link immune changes to a cancer’s spread through the body, but find no role for so-called “driver” mutations.

The biotech firm Celgene inks a huge collaboration deal with Juno Therapeutics to develop and commercialize new cancer immunotherapies.

Holding laboratory mice at temperatures lower than those the animals prefer could be altering their physiology and skewing experimental results.

Turning a patient’s immune cells into cancer-fighting weapons

Six institutions will split a $540 million donation to study cancer immunotherapy among other things.  

Research Associate, Perelman School of Medicine, University of Pennsylvania. Age: 27